文献速递肝肾功能剂量调整特殊人群用药

HSK7653单剂在肾功能正常或受损中国受试者中的药动学、药效学与安全性

Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function.
PubMed 文献 · Clin Pharmacokinet · 2024-01-06

本研究为多中心、开放、非随机、平行对照I期临床试验,比较单次口服HSK7653在轻度、中度、重度肾功能不全及终末期肾病患者与肾功能正常受试者中的药动学、药效学与安全性。结果显示HSK7653暴露量不随肾功能损害严重程度显著改变,药效学抑制率曲线相似,各组合耐受且无严重不良事件,提示肾功能不全患者可能无需调整剂量。

要点

  • HSK7653暴露量(Cmax、AUC0-t、AUC0-inf)不随肾功能损害严重程度显著改变
  • 肾清除率随肾功能损害严重程度呈一定下降趋势
  • 各肾功能组DPP-4抑制率-时间曲线相似,安全耐受良好

核心结论

  • HSK7653为长效口服DPP-4抑制剂,支持每2周一次给药方案。
  • 单次给药后肾功能损害未明显影响HSK7653在中国受试者中的药动学与药效学特性。
  • HSK7653耐受性良好,不良事件未随肾功能损害加重而增加,提示肾功能不全患者可能无需调整剂量。

研究设计与样本

  • 多中心、开放标签、非随机、平行对照I期临床研究。
  • 共42例受试者:轻度肾功能不全8例、中度10例、重度10例、终末期肾病(未透析)5例,匹配的肾功能正常对照9例。
  • 单次口服HSK7653后评估药动学、基于DPP-4抑制率的药效学及全程安全性。

主要发现

  • HSK7653的Cmax、AUC0-t、AUC0-inf在不同肾功能损害严重程度组间未见显著差异。
  • 肾清除率(CLR)随肾功能损害严重程度呈一定下降趋势,重度肾功能不全组与终末期肾病组CLR基本相似。
  • DPP-4抑制率-时间曲线在各肾功能组间相似。
  • 所有组安全性良好,未发生严重不良事件。

关键数值与推荐

  • HSK7653暴露参数包括Cmax、AUC0-t、AUC0-inf,未报告具体数值。
  • 药效学以DPP-4抑制率评估,组间曲线相似。
  • 安全性评价显示无严重不良事件发生。

临床怎么用

  • HSK7653单次给药后肾功能损害未显著影响其药动学与药效学,提示肾功能不全患者可能无需调整剂量。
  • HSK7653支持每2周一次给药方案,适用于2型糖尿病治疗。
  • 临床使用中仍需关注肾功能损害患者的个体化评估与安全性监测。

局限性

  • 本研究为单次给药设计,未评估多次给药后的药动学与药效学。
  • 终末期肾病组样本量较小(5例),且未纳入透析患者。
  • 研究仅在中国受试者中进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: HSK7653 is a novel, ultralong-acting dipeptidyl peptidase-4 (DPP-4) inhibitor, promising for type 2 diabetes mellitus with a dosing regimen of once every 2 weeks. This trial investigates the pharmacokinetics (PKs), pharmacodynamics (PDs),and safety of HSK7653 in outpatients with normal or impaired renal function. METHODS: This is a multicenter, open-label, nonrandomized, parallel-controlled phase I clinical study that investigates the pharmacokinetic profiles of HSK7653 after a single oral administration in 42 subjects with mild (n = 8), moderate (n = 10), severe renal impairment (n = 10), and end-stage renal disease (without dialysis, n = 5) compared with matched control subjects with normal renal function (n = 9). Safety was evaluated throughout the study, and the pharmacodynamic effects were assessed on the basis of a DPP-4 inhibition rate. RESULTS: HSK7653 exposure levels including the maximum plasma concentration (Cmax), area under the plasma concentration-time curve from zero to last time of quantifiable concentration (AUC0-t), and area under the plasma concentration-time curve from zero to infinity (AUC0-inf) showed no significant differences related to the severity of renal impairment. Renal clearance (CLR) showed a certain downtrend along with the severity of renal impairment. The CLR of the group with severe renal impairment and the group with end-stage renal disease were basically similar. The DPP-4 inhibition rate-time curve graph was similar among the renal function groups. All groups had favorable safety, and no serious adverse events occurred. CONCLUSIONS: HSK7653 is a potent oral DPP-4 inhibitor with a long plasma half-life, supporting a dosing regimen of once every 2 weeks. Impaired renal function does not appear to impact the pharmacokinetic and pharmacodynamic properties of HSK7653 after a single administration in Chinese subjects. HSK7653 is also well tolerated without an increase in adverse events with increasing renal impairment. These results indicate that dose adjustment of HSK7653 may not be required in patients with renal impairment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05497297.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Shi D, Chen L, Li G, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function. Clin Pharmacokinet. 2024. PMID: 38184489. doi:10.1007/s40262-023-01333-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。